Compare

Compare stocks side by side

Pick up to 3 companies to see where each one is stronger or weaker.

ALLRADMA

Allarity Therapeutics, Inc.

Area by area

Overall Quant Score

How does it look overall? (out of 100)

ALLR

42/100

ADMA

77/100

Quality

Is it a profitable, well-run business?

ALLR

2.0/10

ADMA

9.8/10

Growth

Is the company growing?

ALLR

6.7/10

ADMA

5.2/10

Valuation

Is the price reasonable? (higher = cheaper)

ALLR

5.0/10

ADMA

6.7/10

Risk

How risky are the shares? (higher = lower risk)

ALLR

5.0/10

ADMA

4.8/10

Momentum

Is the share price trending up?

ALLR

4.6/10

ADMA

7.7/10

Financial strength

Is the balance sheet healthy?

ALLR

0.4/10

ADMA

8.9/10

The balanced view

Model-generated

Allarity Therapeutics, Inc.

This company scores below average, with solid growth, although its balance sheet looks stretched.

Leads on: growth, risk

Best feature: solid growth (Net income growth (FY): 54.2%)

Watch out: balance sheet is stretched (Piotroski F-Score: 1/9)

ADMA Biologics, Inc.

This company scores well across most areas, with supportive analyst views and strong profitability.

Leads on: quality, valuation, momentum, financial strength

Best feature: analysts broadly positive (Analyst buy share: 90%)

Watch out: weakest area: risk profile (Largest 1Y drawdown: -63%)

Different strengths suit different goals — a higher score in one area doesn’t make a stock the better choice for everyone.